Patents by Inventor Heinz Fretz

Heinz Fretz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11839613
    Abstract: The present invention relates to pyrimidine derivatives of formula (I) wherein (R1)n, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description and their use in the treatment of cancer by modulating an immune response comprising a reactivation of the immune system in the tumor. The invention further relates to novel benzofurane and benzothiophene derivatives of formula (II) and their use as pharmaceuticals, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.
    Type: Grant
    Filed: May 17, 2018
    Date of Patent: December 12, 2023
    Assignee: Idorsia Pharmaceuticals Ltd
    Inventors: Christoph Boss, Olivier Corminboeuf, Heinz Fretz, Isabelle Lyothier, Davide Pozzi, Sylvia Richard-Bildstein, Hervé Siendt, Thierry Sifferlen
  • Patent number: 11712438
    Abstract: The present invention relates to phenyl derivatives of formula (I) wherein (R1)n, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description and their use in the treatment of cancer by modulating an immune response comprising a reactivation of the immune system in the tumor. The invention further relates to novel benzofurane and benzothiophene derivatives of formula (III) and their use as pharmaceuticals, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.
    Type: Grant
    Filed: May 17, 2018
    Date of Patent: August 1, 2023
    Assignee: Idorsia Pharmaceuticals Ltd
    Inventors: Christoph Boss, Olivier Corminboeuf, Heinz Fretz, Isabelle Lyothier, Davide Pozzi, Sylvia Richard-Bildstein, Hervé Siendt, Thierry Sifferlen
  • Publication number: 20230165859
    Abstract: The present invention relates to derivatives of formula (I) wherein R1, and R2 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptor EP2.
    Type: Application
    Filed: November 27, 2022
    Publication date: June 1, 2023
    Inventors: Heinz FRETZ, Isabelle LYOTHIER, Julien POTHIER, Sylvia RICHARD-BILDSTEIN, Thierry SIFFERLEN
  • Patent number: 11446298
    Abstract: The present invention relates to pyrimidine derivatives of formula (I) wherein (R1)n, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description and their use in the treatment of cancer by modulating an immune response comprising a reactivation of the immune system in the tumor. The invention further relates to novel benzofurane and benzothiophene derivatives of formula (III) and their use as pharmaceuticals, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.
    Type: Grant
    Filed: May 17, 2018
    Date of Patent: September 20, 2022
    Assignee: IDORSIA PHARMACEUTICALS LTD
    Inventors: Christoph Boss, Olivier Corminboeuf, Heinz Fretz, Isabelle Lyothier, Davide Pozzi, Sylvia Richard-Bildstein, Hervé Siendt, Thierry Sifferlen
  • Publication number: 20220175775
    Abstract: The present invention relates to derivatives of formula (I) wherein (R1)n, R2, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.
    Type: Application
    Filed: December 13, 2021
    Publication date: June 9, 2022
    Applicant: Idorsia Pharmaceuticals Ltd
    Inventors: Heinz FRETZ, Isabelle LYOTHIER, Julien POTHIER, Sylvia RICHARD-BILDSTEIN, Thierry SIFFERLEN, Lorenza WYDER PETERS, Davide POZZI, Olivier CORMINBOEUF
  • Patent number: 11325899
    Abstract: The present invention relates to benzofurane and benzothiophene derivatives of formula (I) wherein (R1)n, R2, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description and their use in the treatment of cancer by modulating an immune response comprising a reactivation of the immune system in the tumor. The invention further relates to novel benzofurane and benzothiophene derivatives of formula (II) and their use as pharmaceuticals, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.
    Type: Grant
    Filed: May 17, 2018
    Date of Patent: May 10, 2022
    Assignee: IDORSIA PHARMACEUTICALS LTD
    Inventors: Christoph Boss, Olivier Corminboeuf, Heinz Fretz, Isabelle Lyothier, Davide Pozzi, Sylvia Richard-Bildstein, Hervé Siendt, Thierry Sifferlen
  • Patent number: 11241431
    Abstract: The present invention relates to derivatives of formula (I) wherein (R1)n, R2, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: February 8, 2022
    Assignee: IDORSIA PHARMACEUTICALS LTD
    Inventors: Heinz Fretz, Isabelle Lyothier, Julien Pothier, Sylvia Richard-Bildstein, Thierry Sifferlen, Lorenza Wyder Peters, Davide Pozzi, Olivier Corminboeuf
  • Publication number: 20210113559
    Abstract: The present invention relates to pyrimidine derivatives of formula (I) wherein (R1)n, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description and their use in the treatment of cancer by modulating an immune response comprising a reactivation of the immune system in the tumor. The invention further relates to novel benzofurane and benzothiophene derivatives of formula (II) and their use as pharmaceuticals, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.
    Type: Application
    Filed: May 17, 2018
    Publication date: April 22, 2021
    Inventors: Christoph BOSS, Olivier CORMINBOEUF, Heinz FRETZ, Isabelle LYOTHIER, Davide POZZI, Sylvia RICHARD-BILDSTEIN, Hervé SIENDT, Thierry SIFFERLEN
  • Publication number: 20210115031
    Abstract: The present invention relates to benzofurane and benzothiophene derivatives of formula (I) wherein (R1)n, R2, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description and their use in the treatment of cancer by modulating an immune response comprising a reactivation of the immune system in the tumor. The invention further relates to novel benzofurane and benzothiophene derivatives of formula (II) and their use as pharmaceuticals, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.
    Type: Application
    Filed: May 17, 2018
    Publication date: April 22, 2021
    Inventors: Christoph BOSS, Olivier CORMINBOEUF, Heinz FRETZ, Isabelle LYOTHIER, Davide POZZI, Sylvia RICHARD-BILDSTEIN, Hervé SIENDT, Thierry SIFFERLEN
  • Publication number: 20200289507
    Abstract: The present invention relates to derivatives of formula (I) wherein (R1)n, R2, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.
    Type: Application
    Filed: November 17, 2016
    Publication date: September 17, 2020
    Applicant: Idorsia Pharmaceuticals Ltd
    Inventors: Heinz FRETZ, Isabelle LYOTHIER, Julien POTHIER, Sylvia RICHARD-BILDSTEIN, Thierry SIFFERLEN, Lorenza WYDER PETERS, Davide POZZI, Olivier CORMINBOEUF
  • Publication number: 20200179383
    Abstract: The present invention relates to phenyl derivatives of formula (I) wherein (R1)a, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description and their use in the treatment of cancer by modulating an immune response comprising a reactivation of the immune system in the tumor. The invention further relates to novel benzofurane and benzothiophene derivatives of formula (III) and their use as pharmaceuticals, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.
    Type: Application
    Filed: May 17, 2018
    Publication date: June 11, 2020
    Inventors: Christoph BOSS, Olivier CORMINBOEUF, Heinz FRETZ, Isabelle LYOTHIER, Davide POZZI, Sylvia RICHARD-BILDSTEIN, Hervé SIENDT, Thierry SIFFERLEN
  • Publication number: 20200108068
    Abstract: The present invention relates to pyrimidine derivatives of formula (I) wherein (R1)n, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description and their use in the treatment of cancer by modulating an immune response comprising a reactivation of the immune system in the tumor. The invention further relates to novel benzofurane and benzothiophene derivatives of formula (III) and their use as pharmaceuticals, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.
    Type: Application
    Filed: May 17, 2018
    Publication date: April 9, 2020
    Inventors: Christoph BOSS, Olivier CORMINBOEUF, Heinz FRETZ, Isabelle LYOTHIER, Davide POZZI, Sylvia RICHARD-BILDSTEIN, Hervé SIENDT, Thierry SIFFERLEN
  • Publication number: 20200069686
    Abstract: The present invention relates to derivatives of formula (I) wherein R1, and R2 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptor EP2.
    Type: Application
    Filed: May 17, 2018
    Publication date: March 5, 2020
    Inventors: Heinz FRETZ, Isabelle LYOTHIER, Julien POTHIER, Sylvia RICHARD-BILDSTEIN, Thierry SIFFERLEN
  • Patent number: 9920010
    Abstract: The present invention relates to derivatives of formula (I) wherein (R1)n, R2a, R2b, R3a, R3b, R4, L1, L2, X, Y and Ar1 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as CXCR7 receptor modulators.
    Type: Grant
    Filed: May 28, 2014
    Date of Patent: March 20, 2018
    Assignee: IDORSIA PHARMACEUTICALS LTD
    Inventors: Heinz Fretz, Philippe Guerry, Thierry Kimmerlin, Francois Lehembre, Julien Pothier, Hervé Siendt, Anja Valdenaire
  • Patent number: 9428456
    Abstract: The present invention relates to 1-[m-carboxamido(hetero)aryl-methyl]-heterocycyl-carboxamide compounds of formula (I) wherein X, Ar1, R1, R2, R3, R4, R5a, R5b and p are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as CXCR7 receptor modulators.
    Type: Grant
    Filed: June 21, 2013
    Date of Patent: August 30, 2016
    Assignee: ACTELION PHARMACEUTICALS LTD
    Inventors: Heinz Fretz, Markus Gude, Philippe Guerry, Thierry Kimmerlin, Francois Lehembre, Thomas Pfeifer, Anja Valdenaire
  • Publication number: 20160107997
    Abstract: The present invention relates to derivatives of formula (I) wherein (R1)n, R2a, R2b, R3a, R3b, R4, L1, L2, X, Y and Ar1 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as CXCR7 receptor modulators.
    Type: Application
    Filed: May 28, 2014
    Publication date: April 21, 2016
    Inventors: Heinz FRETZ, Philippe GUERRY, Thierry KIMMERLIN, Francois LEHEMBRE, Julien POTHIER, Hervé SIENDT, Anja VALDENAIRE
  • Publication number: 20150336893
    Abstract: The present invention relates to 1-[m-carboxamido(hetero)aryl-methyl]-heterocycyl-carboxamide compounds of formula (I) wherein X, Ar1, R1, R2, R3, R4, R5a, R5b and p are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as CXCR7 receptor modulators.
    Type: Application
    Filed: June 21, 2013
    Publication date: November 26, 2015
    Inventors: Heinz FRETZ, Markus GUDE, Philippe GUERRY, Thierry KIMMERLIN, Francois LEHEMBRE, Thomas PFEIFER, Anja VALDENAIRE
  • Patent number: 8697869
    Abstract: The present invention relates to 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9H-carbazole derivatives of the formula (I), wherein R1, R2 and R3 are as described in the description and their use as prostaglandin receptor modulators, most particularly as prostaglandin D2 receptor modulators, in the treatment of various prostaglandin-mediated diseases and disorders, to pharmaceutical compositions containing these compounds and to processes for their preparation.
    Type: Grant
    Filed: March 21, 2011
    Date of Patent: April 15, 2014
    Assignee: Actelion Pharmaceuticals Ltd.
    Inventors: Hamed Aissaoui, Heinz Fretz, Julien Hazemann, Sylvia Richard-Bildstein, Romain Siegrist
  • Publication number: 20130345199
    Abstract: The present invention relates to 1-[m-Carboxamido(hetero)aryl-methyl]-piperidine-4-carboxamide derivatives of formula (I) wherein X, Ar1, R1, R2, R3, R4, R5 and p are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as CXCR7 receptor modulators.
    Type: Application
    Filed: June 21, 2013
    Publication date: December 26, 2013
    Applicant: Actelion Pharmaceuticals Ltd.
    Inventors: Heinz FRETZ, Markus Gude, Philippe Guerry, Thierry Kimmerlin, Francois Lehembre, Thomas Pfeifer, Anja Valdenaire
  • Patent number: 8575158
    Abstract: The present invention relates to 1-phenyl-substituted heterocyclyl derivatives of the formula (I), wherein X, Y, Z, n, R1, R2, R3, R4, R5, R6, R7 and R10 are as described in the description and their use as prostaglandin receptor modulators, most particularly as prostaglandin D2 receptor modulators, in the treatment of various prostaglandin-mediated diseases and disorders, to pharmaceutical compositions containing these compounds and to processes for their preparation.
    Type: Grant
    Filed: July 4, 2011
    Date of Patent: November 5, 2013
    Assignee: Actelion Pharmaceuticals Ltd.
    Inventors: Hamed Aissaoui, Christoph Boss, Heinz Fretz, Julien Pothier, Sylvia Richard-Bildstein, Philippe Risch, Romain Siegrist